There is a good deal of commentary about what happened at the nationally in this year’s election cycle. But a good deal happened at the state level as well – things that will impact healthcare and may influence how other states respond. In addition, there were state issues that were voted on that could have an impact on the national debate of some specific topics. All in all, according to Ballotpedia, there were 154 measures available for voters to consider across the states this November, and a number of them touched on healthcare.
In that capacity, here are a few the state ballot initiatives that are of note:
- Prop 61 – California – Pharma Pricing – This proposition would have required state agencies to pay either the same or a lower price for prescription drugs than the U.S. Department of Veteran Affairs . The measure was seen as a focal point on the issue of pharmaceutical pricing. The measure failed with 54 percent against to 46 percent in favor.
- Amendment 69 – Colorado – Single Payer - This measure would have created a single payer healthcare system called ColoradoCare that would provide universal healthcare for residents of the state and financed through a tax on wage and non-wage income. The measure was soundly defeated by nearly 80 percent against to 20 percent in favor.
- Proposition 60 – California – Condoms in Pornography – Certainly one of the more unusual ballot initiatives voted on this cycle involved a proposal to require actors in pornography films to be given condoms to wear during performances and would further have required the makers of the films to cover the costs of medical screenings and examinations. The measure failed with nearly 54 percent against compared to 46 percent in favor.
- Proposition 106 — Colorado – End of Life – This ballot measure sets up standards that would allow residents to legally seek and obtain assistance to end their life through the self administration of drugs when facing the circumstance of a terminal illness. The measure passed by nearly 65 percent in favor to 35 percent opposed.
- Multiple – Medical Marijuana - There were a number of marijuana legalization ballot initiatives, some of which were about recreational use, but several of which were specific to medical need -
- Arkansas Issue 6 – allows medical use of marijuana for 17 specific qualifying medical conditions, passed 53 percent in favor with nearly 47 percent opposed;
- Florida Amendment 2 - would allow the regulation of marijuana by the state and use by patients with qualifying conditions such as HIV/AIDS, glaucoma, Parkinson’s Disease, PTSD, ALS, MS, cancer and epilepsy- passed 71 percent to 29 percent;
- Montana Medical Marijuana Initiative – would amend existing law passed by the legislature to remove existing numerical restrictions on medical marijuana providers who had been limited to the number of patients they could serve, among other things – Passed by nearly 57 percent to 43 percent;
- North Dakota Medical Marijuana Legalization Initiative – Sets up regulation of cultivation and distribution for medical marijuana for patients of specific medical conditions passed by nearly 64 percent to 36 percent.
- Soda and Sugary Beverage Taxes - While a significant yes regarding the use of medical marijuana, there was also support for a tax to be placed on soda and beverages containing sugar in four municipalities. The taxes work by leveraging a tax on the ounce for specified types of beverages and the municipalities where the measures passed primarily in California – San Francisco (62 percent in favor, 38 percent opposed), Oakland (61 percent in favor and 39 percent opposed) and Albany (71 percent in favor, 29 percent opposed) and one in Boulder Colorado (don’t have the percents).
All of percentages were gleaned from the site Ballotpedia and were rounded up.
We are almost through it! Just a few more days.
In the meantime, the more enjoyable aspects of autumn, chilly nights, fires in the fireplace, and brilliant leaves are all upon us. Soon the end of year holidays will be upon us. In the meantime, a few interesting things from the week:
- OPDP Issues Fifth Warning/Untitled Letter of 2016 – To say that it has been an anemic year from OPDP’s enforcement letters is a bit of an understatement. This week the agency issued its fifth of the year and if it does not double that number in the next few weeks, it will be the lowest level of enforcement seen from this office of FDA. The untitled letter cited a video for Oxtellar XR – an extended release tablet indicated for adjunctive therapy of partial seizures in adults and children 6-17 years. The product has some specific risks associated with use in the label, including warnigns of anaphylactic reactions among others. The video was cited for a lack of adequate diretions for use because of the specific language used in the video that OPDP felt broadened the indication of the compound to include all seizure types and because the presentation did not present risk information in conjunction with the benefits. Of the five letters issued this year, four were Untitled Letters and one was a Warning Letter.
- AdComm Gives Up Vote on Nocturia Candidate – A meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee voted 14-4 in favor of the benefit/risk profile of SER120 (desmopressin nasal spray) for the treatment of nocturia – a condition in which adults awaken two or more times a night to urinate. If approved, it would be the first treatment approved for nocturia, though there have been previous attempts. In January 2015, a tablet formulation put forth by a different company and reviewed by a different advisory committee, resulted in a negative recommendation.
- How Much of the Economy is Regulated by FDA? For many years, many people (including this people) have touted the characterization that FDA regulates one-fourth of the U.S. economy – or in other words, regulates 25 cents of every dollar spent. In a blog posting this week, FDA put that characterization to pasture with a new study by the agency’s staff economists that takes it down a peg – with FDA regulating one-fifth of the economy, or 20 cents of every dollar spent – a level that has apparently held steady over the past five years. The study was done analyzing expenditure data from the Bureau of Economic Analysis (BEA). I stand corrected.
Enjoy the weekend everyone. And get out and vote, if you haven’t already.
It has been way too long since a Weekly Roundup and way too long since a regular posting. The autumn has turned out to be an exceptionally busy time so apologies on both fronts. But today I’m carving out a little time to at least get out a Roundup and hopefully will have a few new postings next week regarding some things on my mind.
In the meantime, we are getting up in darkness and switching out our closets from summer wear to autumnal clothing. Upstate New York has seen some snow. In the mid-Atlantic, we have had some chilly mornings. And on Monday we will hand out candy to costumed little ones counting on our answering the doorbell. In the meantime, here is a bit of what has transpired at FDA:
- Male Hormones, Female Sex-drive and Guidance – A couple of things on this front. This week FDA issued class-wide labeling changes for testosterone and other anabolic steroids to include expanded warnings, stating a possible association with abuse and dependence and citing specific potential among adults and adolescents engaged in body building and warning of a number of adverse associations. Also this week, the agency issued guidance entitled “Low Sexual Interest, Desire, and/or Arousal in Women: Developing Drugs for Treatment” to assist sponsors in what has been an often elusive category in the development of treatments for women. The guidance provides overall thinking toward a clinical trials, with specific focus on Phase III trial designs.
- Accelerated Approval for Soft Tissue Carcinoma Treatment – A new treatment – Lartruvo – with breakthrough therapy status, priority review and fast track designation won accelerated approval this week for the treatment of certain types of soft tissue carcinoma (STS). In the FDA release, Lartruvo is described as a platelet-derived growth factor receptor-alpha blocking antibody which may help slow or stop tumor growth by blocking receptors that cause growth. Lartruvo also has orphan drug status, with the National Cancer Institute estimating that 12,310 new cases and 5,000 deaths will occur in 2016. Lartruvo is approved for use with chemotherapy in STS for patients who cannot be cured with radiation or surgery and who have a type of STS for which chemotherapy is an appropriate treatment. You can read the company press release here.
- First Line Treatment for Immunotherapy in NSCLC – Keytruda, a compound under study for multiple types of cancer, received FDA approval as a first-line treatment of metastatic non-small cell lung cancer in patients who have a high PD-L1 expression over 50 percent. The approval was granted after studies showed improved survival time over chemotherapy. The company press release can be found here.
That’s it for me this week. Have a great weekend everyone.
The shifting of gears is happening before our eyes. Already leaves are falling and the morning alarm goes off in the final moments of night time darkness rather than the first rays of morning sunshine. The trees are signalling that they are ready for their slumber. I have been too – away on a Equinox vacation. I’m back, so let’s see what happened not just over the past week, but two.
Or first, what didn’t happen. There were no new OPDP action letters posted these past few weeks, but we are now up to four for what is shaping up to be a new low in the number of enforcement letters posted by the office.
But a few things did happen and here are some that I wanted to highlight:
- FDA Approves First Drug to Treat Duchenne’s Muscular Dystrophy – It was perhaps one of the more anticipated decisions by FDA on a product this year. That was because it treats a rare, yet devastating condition in children where there were no options. And it was because the clinical trial was small. And because these and other factors would cause FDA to step outside of its usual approach in considering new approvals. Amid media reports of internal dissension within the agency, and after some delay, FDA ultimately announced approval of Exondys 51 for the treatment of a subset of people with Duchenne’s Muscular Dystrophy (DMD) who have a specific gene mutation (about 13 percent of the DMD population). The compound had fast track, orphan drug and priority review designation. The company stated in its release on the approval that a clinical benefit has not yet been established for the treatment and that continued approval may be contingent upon seeing that benefit in future confirmatory trials.
- Automated Insulin Delivery Device Approved - Hailed as the first “artificial pancreas”, FDA this week announced that it was giving the ok to the first device designed to do what the pancreas does – to deliver insulin to the body on a regular basis. The device, the MiniMed 670G hybrid closed loop system, is equipped with a sensor to monitor glucose levels and deliver insulin through an infusion patch connected to an insulin pump, worn externally. The device was studied in a trial consisting of 123 people. The indication is in patients 14 years and older with Type 1 diabetes and the agency will be looking for a post-market study to get a clearer picture on actual use in the real world. Details and photos on the use and range of the device can be found on the company site. The company says the new system will be ready for shipping in Spring, 2017.
- The “Close-Hold Embargo” and FDA – Anyone working in media is familiar with a news embargo. It allows an entity with news to share it with reporters prior to an official announcement so that stories can be ready for publication when the news actually happens. It is a handy tool for both sides. Add the words “close-hold” prior to the word embargo, however, and you have controversy. That is what happened with the publication of an article detailing a practice at FDA known as the “close-hold embargo” whereby the news was not only embargoed, but the ability for a reporter to talk to others to get input and point of view to help shape the story was also proscribed. The idea that a federal agency would tell reporters who to report the news – or to intervene in the reporting process brought to light by the article, generated a good deal of critical comment during the course of the week. Agree with it or not, it may not be perceived as bolstering the notion of transparency.
That’s it for me this week. Have a good weekend everyone. Happy Autumn!